Utilizing Nanoparticles in Cancer Immunotherapy: Innovations and Challenges
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (29 March 2024) | Viewed by 1171
Special Issue Editors
Interests: biological mechanisms of cancer progression and metastasis; development of novel drugs; targeted delivery of therapeutic agents (from nano-sized systems up to medical devices); developing patient-derived; tissue engineered pre-clinical models to study cancer
Interests: immune cell signaling; T cell biology; tumor immunology; immune regulation; autoimmune diseases
Special Issue Information
Dear Colleagues,
This Special Issue, entitled “Utilizing Nanoparticles in Cancer Immunotherapy”, aims to act as a comprehensive guide that provides insight into the innovative incorporation of nanotechnology into cancer immunotherapy. This resource elucidates how nanoparticles enhance the delivery and efficacy of immunotherapeutic agents, including peptides, antibodies, small molecules, and nucleic acids. It showcases the potential of nanoparticles in modulating the tumor microenvironment, improving antigen transport to immune cells, and inducing immunogenic cell death. Additionally, this Special Issue discusses novel nanotechnological strategies for overcoming the limitations of traditional immunotherapies, such as low response rates and side effects. Cutting-edge developments like stimulus-responsive nanocarriers and combinatorial therapies are examined for their potential in combating cancer resistance. Lastly, this Special Issue outlines the current clinical applications and the future trajectory of nanoparticles in cancer immunotherapy by covering the following topics:
- Introduction to nanoparticles and their role in immunotherapy;
- Types of nanoparticles and their biomedical applications;
- Enhancing the delivery of immunotherapeutic agents through nanoparticles;
- Modulating the tumor microenvironment (TME) with nanoparticles;
- Improving antigen transport and presentation via nanoparticles;
- Inducing immunogenic cell death using nanoparticle-based strategies;
- Overcoming limitations of traditional immunotherapies through nanotechnology;
- Stimulus-responsive nanocarriers and their role in targeted therapy;
- Combinatorial therapies: integrating nanoparticles with other treatment modalities;
- Current clinical applications and future prospects of nanoparticles in cancer immunotherapy.
Prof. Dr. Abdel Kareem Azab
Prof. Dr. Linrong Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticles
- cancer immunotherapy
- tumor microenvironment
- targeted drug delivery
- combinatorial therapies
